<DOC>
	<DOCNO>NCT02077933</DOCNO>
	<brief_summary>Dose escalation part : determine high dose alpelisib administer daily basis give combination daily everolimus combination daily everolimus exemestane . Dose expansion part : To describe safety tolerability alpelisib everolimus alpelisib , everolimus exemestane combination .</brief_summary>
	<brief_title>Study Safety Efficacy Alpelisib With Everolimus Alpelisib With Everolimus Exemestane Advanced Breast Cancer Patients , Renal Cell Cancer Pancreatic Tumors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria For entire trial : Adult &gt; = 18 year old sign Informed Consent Form tumor tissue available analysis describe protocol Eastern Cooperative Oncology Group performance status ≤2 adequate bone marrow organ function define protocol able swallow retain oral medication either measurable nonmeasurable disease per RECIST 1.1 . Inclusion Criteria BYL719+ Everolimus combination escalation phase plus histologically/cytologically confirm metastatic and/or recurrent solid tumor standard therapy exists . Inclusion Criteria BYL719+ Everolimus combination expansion phase , renal cell carcinoma cohort first 7 criterion plus histologically/cytologically confirm Renal Cell Cancer detail protocol Inclusion Criteria BYL719+ Everolimus combination expansion phase , pancreatic NeuroEndocrine Tumor cohort first 7 criterion plus histologically/cytologically confirm pancreatic NeuroEndocrine Tumor detail protocol Inclusion Criteria BYL719+ Everolimus combination expansion phase , mTOR inhibitorpretreated patient ' cohort first 7 criterion plus histologically and/or cytologically confirm solid malignancy describe protocol Inclusion Criteria breast cancer cohorts escalation expansion phase , first 7 criterion plus postmenopausal histologically and/or cytologically confirm diagnosis breast cancer describe protocol Specific Inclusion Criteria time crossover ( breast cancer , expansion phase ) , Patient randomize alpelisib exemestane combination radiologically document progressive disease detail protocol Patient receive previous treatment PI3K and/or AKT and/or mTOR inhibitor ( mTOR inhibitor allow expansion cohort patient areceived prior mTOR inhibitor ) Known intolerance hypersensitivity Everolimus rapamycin analogs Patient primary central nervous system ( CNS ) tumor CNS tumor involvement detail protocol Patient diabetes mellitus , document steroidinduced diabetes mellitus Patient history another malignancy within 2 year prior start study treatment describe protocol Patient recover grade 1 good ( except alopecia ) relate side effect prior antineoplastic therapy detail protocol Patient systemic therapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior start study treatment Patient receive radiotherapy ≤ 4 week prior start study drug , exception palliative radiotherapy ( ≤ 2 week prior start study drug ) , recover side effect therapy baseline Grade ≤ 1 and/or ≥ 30 % bone marrow irradiate Patient undergone major surgery ≤ 4 week prior start study treatment recover side effect procedure Patient clinically significant cardiac disease impair cardiac function severe and/or uncontrolled medical condition detail protocol Patient currently receive medication know risk prolong QT interval induce Torsades de Pointes ( TdP ) treatment either discontinue switched different medication prior start study drug treatment Patient participate prior investigational study within 30 day prior enrollment describe protocol Patient currently receive treatment drug know moderate strong inhibitor inducer isoenzymes CYP34A CYP2C8 describe protocol . Switching different medication prior start treatment allow Patient impair gastrointestinal ( GI ) function GI disease may significantly alter absorption oral alpelisib , everolimus , exemestane Patient know positive serology human immunodeficiency virus Patients receive live attenuate vaccine within 1 week start study drug study specify protocol . Pregnant nursing ( lactate ) woman detail protocol . Patient apply highly effective contraception study duration define protocol Patients mTOR inhibitorpretreated cohort : first 19 criterion plus discontinue prior mTOR inhibitor therapy due nontolerable toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>pancreatic neuroendocrine tumor</keyword>
	<keyword>breast cancer</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>BYL719</keyword>
	<keyword>alpelisib</keyword>
	<keyword>everolimus</keyword>
	<keyword>exemestane</keyword>
</DOC>